Romiplostim increases the platelet count response in adult patients with chronic immune thrombocytopenia (ITP)

Treatment	Overall platelet response
Treatment	Splenectomized (63)	Non-splenectomized (62)	Total (125)
Placebo	0.0 percent (21)	14.3 percent (21)	7.1 percent (42)
Romiplostim	78.6 percent (42)*	87.8 percent (41)*	83.1 percent (83)*

Splenectomized and non-splenectomized adult patients with chronic ITP were treated for 24 weeks in a blinded, controlled study with romiplostim or placebo. The overall platelet response (weekly platelet count >50,000/microL for four or more of the 24 weeks of the study) is shown in this table. Numbers of patients in each group are shown in parentheses.

* All comparisons were statistically significant, with p<0.0001.

Data from: Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395.

Graphic 55815 Version 8.0

خرید پکیج

Romiplostim increases the platelet count response in adult patients with chronic immune thrombocytopenia (ITP)